In vivo evaluation of a novel alginate dressing.
Alginate dressings are currently used in the management of epidermal and dermal wounds, and provide a moist environment that leads to rapid granulation and reepithelialization. However, a cytotoxic effect on proliferation of fibroblasts and residual material with inflammation in healing wounds have been reported recently. We have developed a new alginate dressing (AGA-100), which does not have an inhibitory effect on proliferation of fibroblasts. The purpose of this study was to evaluate the new alginate dressing with respect to wound healing in full- and partial-thickness pig wounds and with respect to biodegradation following implantation into rabbit muscle. Kaltostat and Sorbsan, both well-established commercial dressings, were used as control. The closure rate of full-thickness wounds treated with AGA-100 was significantly higher on day 15 compared with that with Kaltostat and Sorbsan. Reepithelialization rate of partial-thickness wounds treated with Sorbsan was statistically significantly lower on day 3 than those with the other two dressings. As to dressing debris remained in the healing wound, a large amount of foreign debris was noted in all the full-thickness wounds treated with Kaltostat or Sorbsan, while only about one-third of wounds treated with AGA-100 showed a little dressing debris. AGA-100 implanted into the muscle of rabbits was bioresorbed completely within 3 months. Therefore, dressing residue in AGA-100-treated full-thickness wounds might be fully absorbed in a few months. In conclusion, it is shown that our newly developed AGA-100 possesses superior properties compared with typical alginate dressings.
Suzuki
Y
Y
Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan. utsubo@kuhp.kyoto-u.ac.jp
Tanihara
M
M
Nishimura
Y
Y
Suzuki
K
K
Yamawaki
Y
Y
Kudo
H
H
Kakimaru
Y
Y
Shimizu
Y
Y
D000464:Alginates / Q000493:pharmacokinetics; D000818:Animals; D001458:Bandages; D001672:Biocompatible Materials / Q000493:pharmacokinetics; D001673:Biodegradation, Environmental; D002455:Cell Division; D005347:Fibroblasts / Q000473:pathology; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D008297:Male; D008422:Materials Testing; D011817:Rabbits; D012867:Skin / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D013552:Swine; D013997:Time Factors; D014945:Wound Healing
D000464:Alginates; D001672:Biocompatible Materials; D006603:Hexuronic Acids; C078112:sorbsan; D020723:Glucuronic Acid